biostudies-literatureSabei FYNCATS NIH HHSNCI NIH HHS102446https://www.ebi.ac.uk/biostudies/studies/S-EPMC8464505biostudies-literatureUnknown37Ewing's sarcoma (EwS) is the second most common bone cancer in children and adolescents. Current chemotherapy regimens are mainly ineffective in patients with relapsed disease and cause long-term effects in survivors. Therefore, we have developed a combinatorial therapy based on a novel drug candidate named ML111 that exhibits selective activity against EwS cells and synergizes with vincristine. To increase the aqueous solubility of hydrophobic ML111, polymeric nanoparticles (ML111-NP) were developed. In vitro data revealed that ML111-NP compromise viability of EwS cells without affecting non-malignant cells. Furthermore, ML111-NP exhibit strong synergistic effects in a combination with vincristine on EwS cells, while this drug pair exhibits antagonistic effects towards normal cells. FinalNanomedicine : nanotechnology, biology, and medicineA targeted combinatorial therapy for Ewing's sarcoma.PMC8464505R37 CA234006KL2 TR002370R01 CA237569Davare MALeid MEsfandiari Nazzaro ESabei FYPark YVogel WKAl-Fatease AMDemessie AAAlani AAlbarqi HAMoses ASTaratula OfalseA targeted combinatorial therapy for Ewing's sarcoma.Ewing's sarcoma (EwS) is the second most common bone cancer in children and adolescents. Current chemotherapy regimens are mainly ineffective in patients with relapsed disease and cause long-term effects in survivors. Therefore, we have developed a combinatorial therapy based on a novel drug candidate named ML111 that exhibits selective activity against EwS cells and synergizes with vincristine. To increase the aqueous solubility of hydrophobic ML111, polymeric nanoparticles (ML111-NP) were developed. In vitro data revealed that ML111-NP compromise viability of EwS cells without affecting non-malignant cells. Furthermore, ML111-NP exhibit strong synergistic effects in a combination with vincristine on EwS cells, while this drug pair exhibits antagonistic effects towards normal cells. Final2021-01-01T00:00:00Z2021 Oct2026-05-31T15:56:29.08Z2025-04-04T12:46:28.578ZS-EPMC84645053430384010.1016/j.nano.2021.102446